Company Profile
  • 3

    "1000 Talents Plan" Expert

  • 100+

    International patents

  • 170+

    Reseachers

Ascentage Pharma is a global clinical-stage biopharmaceutical company engaged in the discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. 

VIEW MORE
News
Press Release
Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers
Press Release
Yingjie (Jason) Huang, M.D., to Join Ascentage Pharma as Senior Vice President of Clinical Development
ROCKVILLE, Md.andHONG KONG,Sept. 25, 2017/PRNewswire/ --Ascentage Pharma, a global clinical-stage biopharmaceutical company focused on apoptosis-targeted drug discovery and development, today announced thatYingjie (Jason) Huang, M.D., will join the company as Senior Vice President of Clinical Development. Dr. Huang will join Ascentage's senior executive team and will take responsibility for the global development of Ascentage's oncology programs.Dr. Huang has over twenty years of clinical cancer research and drug development experience in the biopharmaceutical industry and academic institution. Prior to joining Ascentage, he served as Senior Medical Director in Global Clinical Development at Novartis, responsible for BRAF/MEK project clinical strategy and clinical development. He actively led clinical projects of Tafinlar/ Mekinist in combination with immunotherapy and targeted therapies at all stages of development. Dr. Huang had also worked in Global Clinical Development as Senior Medical Director and Medical Director at GlaxoSmithKline and Bristol Myer Squibb, respectively. He played a leading role in multiple pivotal global Phase II/III trials in oncology. He contributed to the regulatory approval and life-cycle management for Erbitux, Tykerb in the US or EU, and led the global clinical development activities of brivanib in HCC. Besides the global roles, Dr. Huang had worked as Medical Advisor inAsia Pacificregion at Novartis, he is responsible for the regional clinical development and medical affair activities for Glivec, Femara, Sandostain, and Afinitor. He involved in establishment of clinical research organization and updating skill levels of medical team acrossAsia Pacificregion to enable participation in global development studies and initiation of regional and local clinical studies. Before joining industry, Dr. Huang had been an oncology research fellow atChinese University of Hong Kongand Queen's University inCanada, he had also practiced as physician in oncology at Sun Yat-sen University Cancer Center for six years. Dr. Huang received an M.D. degree from Medical School of Sun Yat-sen University and a Master degree in Clinical Epidemiology from Queen's University inCanada."I am thrilled to welcome Jason to join Ascentage family. He brings a wealth of knowledge and experience in oncology drug development." saidYifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage, "Jason's leadership in clinical development and translational medicine will be instrumental for us to advance our oncology/hematology pipeline on a global basis.""I am very much impressed by Ascentage's science-driven culture and its grit in tackling the once undruggable Protein-Protein Interaction targets," said Dr. Huang. "It is more than exciting to join Ascentage as the company is emerging fast into a global biotech. I look forward to working closely with my passionate colleagues and dedicating my expertise and experience to developing transformational therapeutics for patients worldwide."About Ascentage PharmaAscentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. Ascentage has world-leading proprietary Protein-Protein Interaction drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US,AustraliaandChinaand additional programs in preclinical stages.The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-xLand MDM2-p53, that regulate a tumor cell's programmed cell death program; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics. For more information, please visitwww.ascentagepharma.com.Media and Investors Contactsir@ascentagepharma.com
Press Release
Ascentage Pharma Announces Appointment of Han Li as Chief Financial Officer
HONG KONG, Jul 5, 2017 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company focused on apoptosis-targeted drug discovery and development, today announced the appointment of Han Li, Ph.D., as its Chief Financial Officer. Dr. Li has joined Ascentage Pharma’s senior executive team and will be responsible for the finance, corporate and business development. Dr. Li joins Ascentage from Bayer Pharma AG.“We are delighted to have Han join our team. His extensive experience in drug discovery, pharmaceuticals strategic marketing, business development and equity research on Wall Street will serve well Ascentage for the next phase of corporate growth and development,” said Dajun Yang, M.D., Ph.D., Chairman and CEO of Ascentage. “We look forward to Han’s leadership in developing and executing financial strategy for Ascentage as we advance our product candidates in a fast pace.”Dr. Li has over twenty years of experience in the biopharmaceutical industry and on Wall Street. Prior to Ascentage, he had worked in Strategic Marketing at Bayer Pharmaceuticals, responsible for Strategy and Portfolio Management and commercial development. He had been actively involved in commercial launches of oncology drugs (Stivarga and Xofigo), and various BD&L activities (including Algeta Acquisition and Orion partnership). Before Bayer, Dr. Li had worked on Wall Street as a biotech analyst at Morgan Stanley, Suntrust Robinson Humphrey, and Stanford Financial Group. He was top rated by the StarMine Analyst Ranking for earnings accuracy and stock recommendation of companies under coverage. Prior to that, he was a research scientist at Genentech in drug discovery and was a lead inventor of three international patents on novel cytokines. Dr. Li holds a Ph.D. degree in Pharmacology from Boston University School of Medicine and an M.B.A. degree in Finance from University of California at Los Angeles.“I am impressed with the robust drug discovery platform of Protein-Protein Interaction and science-driven culture at Ascentage.” commented Dr. Li, “I would like to contribute to the future expansion and growth of the Company with my combined experience in biopharma and Wall Street.”About Ascentage PharmaAscentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. Ascentage has world-leading proprietary Protein-Protein Interaction drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-xLand MDM2-p53, that regulate a tumor cell's programmed cell death program; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics. For more information, please visitwww.ascentagepharma.com.http://www.prnewswire.com/news-releases/ascentage-pharma-announces-appointment-of-han-li-as-chief-financial-officer-300483307.html
Press Release
Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
June 26, 2017 – Ascentage Pharma, a global, clinical-stage biopharmaceutical company, announced today that the China Food and Drug Administration (CFDA) granted Investigational New Drug (IND) approval to APG-1252, a novel Bcl-2/Bcl-XLinhibitor which is discovered and developed by Ascentage, for the treatment of cancers. The CFDA received the IND application to APG-1252 at the end of December 2016, and spent less than six months to complete all the review work.APG-1252 is a novel small molecule drug that helps restore programmed cell death process (apoptosis) through selective inhibition of Bcl-2 family members Bcl-2 and Bcl-XL. APG-1252 obtained IND approval from the FDA in December 2016 and is now in Phase I clinical trial in the United States.“Ascentage has been implementing a global development strategy of advancing our programs in both United States and China, in order to accelerate clinical development and to maximize value of our clinical assets.” Yifan Zhai, MD, Ph.D., Chief Medical Officer of Ascentage, commented, “Dual inhibition of both Bcl-2 and Bcl-XLhas distinctly different therapeutic potential from selective inhibition of Bcl-2. The former potentially addresses solid tumors where Bcl-XLis commonly over-expressed whereas the latter one targets only hematologic malignancies.”“The preclinical data of APG-1252 demonstrates good efficacy in Small Cell Lung Cancer (SCLC) for which there is no effective therapy in clinic. APG-1252 holds promise for SCLC patients and we look forward to advancing APG-1252 into clinical development,” said Professor Yi-Long Wu, Principal Investigator of APG-1252, President of Guangdong Lung Cancer Institute, Director of Sun Yat-sen University Cancer Center and President of Chinese Society of Clinical Oncology (CSCO).Ascentage team is one of the forerunners globally in the field of Bcl-2-targeting drug development. Through years of research, Ascentage team gained in-depth knowledge and expertise in Protein-Protein Interactions (PPIs)-targeting drug design and optimization. Ascentage now has a strong clinical pipeline in the apoptosis space with additional compounds in preclinical development.About APG-1252APG-1252 is an investigational small molecule that selectively binds and inhibits Bcl-2 and Bcl-XLproteins which play pivotal roles in regulating programmed cell death (apoptosis). APG-1252 is designed to overcome the commonly seen on-target toxicity of platelets that is due to Bcl-XLinhibition while maintaining strong anti-tumor potency. APG-1252 is being developed by Ascentage Pharma.About Ascentage PharmaAscentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. Ascentage has world-leading proprietary Protein-Protein Interactions (PPIs)-targeting drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-XLand MDM2-p53, that regulate programmed cell death process; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics. For more information, please visitwww.ascentagepharma.com.